عنوان

Aromatase inhibitors /

(Number (ISBN

3764371994 (alk. paper)

(Number (ISBN

3764374187 (e-ISBN)

(Number (ISBN

9783764371999 (alk. paper)

(Number (ISBN

9783764374181 (e-ISBN)

Number

b509314

Title Proper

Aromatase inhibitors /

General Material Designation

[Book]

First Statement of Responsibility

edited by B.J.A. Furr

Place of Publication, Distribution, etc.

Boston :

Name of Publisher, Distributor, etc.

Birkhäuser,

Date of Publication, Distribution, etc.

[2006]

Date of Publication, Distribution, etc.

©2006

Specific Material Designation and Extent of Item

1 online resource (ix, 182 pages) :

Other Physical Details

illustrations.

Series Title

Milestones in drug therapy

Text of Note

Includes bibliographical references and index

Text of Note

Background and development of aromatase inhibitors -- Aromatase inhibitors and models for breast cancer -- Clinical pharmacology of aromatase inhibitors -- Clinical studies with exemestane -- Clinical studies with letrozole -- Clinical studies with anastrozole -- The third-generation aromatase inhibitors: a clinical overview -- Lessons from the ArKO mouse -- Possible additional therapeutic uses of aromatase inhibitors

0

Text of Note

Many breast tumours are dependent upon oestrogen for their development and continued growth. Over the last 25 years hormone therapy has progressed from the irreversible destruction of endocrine glands to the use of drugs that reversibly suppress oestrogen synthesis or action. The inhibition of oestrogen synthesis is most readily achieved by inhibiting the final step in the pathway of oestrogen biosynthesis, the reaction which transforms androgens into oestrogens by creating an aromatic ring in the steroid molecule (hence the enzyme's trivial name, aromatase). Whereas the first aromatase inhibitors to be used therapeutically could be shown to produce drug-induced inhibition of the enzyme and therapeutic benefits in patients with breast cancer, they were not particularly potent and lacked specificity. However, second-generation drugs were developed and most recently third-generation inhibitors have evolved which possess remarkable specificity and potency. Initial results from clinical trials suggest that these agents will become the cornerstones of future endocrine therapy

Text of Note

Mode of access: World Wide Web

Title

Aromatase inhibitors.

International Standard Book Number

3764374187

Title

OhioLINK electronic book center

Title

SpringerLink

Aromatase-- Inhibitors-- Therapeutic use.

Breast-- Cancer-- Chemotherapy.

Aromatase Inhibitors-- therapeutic use.

Breast Neoplasms-- drug therapy.

Furr, B. J. A.

Ohio Library and Information Network.

Date of Transaction

20090406013159.0

Cataloguing Rules (Descriptive Conventions))

rda

Electronic name

[Book]

Y